These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30019390)

  • 1. Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population.
    Jonsson A; Norberg H; Bergdahl E; Lindmark K
    Cardiovasc Ther; 2018 Oct; 36(5):e12459. PubMed ID: 30019390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study.
    Durstenfeld MS; Katz SD; Park H; Blecker S
    BMC Cardiovasc Disord; 2019 Aug; 19(1):194. PubMed ID: 31399059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure.
    Cooper LB; Hammill BG; Peterson ED; Pitt B; Maciejewski ML; Curtis LH; Hernandez AF
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28073850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure in patients with coronary heart disease: Prevalence, characteristics and guideline implementation - Results from the German EuroAspire IV cohort.
    Morbach C; Wagner M; Güntner S; Malsch C; Oezkur M; Wood D; Kotseva K; Leyh R; Ertl G; Karmann W; Heuschmann PU; Störk S
    BMC Cardiovasc Disord; 2017 May; 17(1):108. PubMed ID: 28476146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure.
    Allen LA; Shetterly SM; Peterson PN; Gurwitz JH; Smith DH; Brand DW; Fairclough DL; Rumsfeld JS; Masoudi FA; Magid DJ
    Circ Heart Fail; 2014 Jan; 7(1):43-50. PubMed ID: 24281136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
    Ferreira JP; Rossignol P; Machu JL; Sharma A; Girerd N; Anker SD; Cleland JG; Dickstein K; Filippatos G; Hillege HL; Lang CC; Ter Maaten JM; Metra M; Ng L; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Voors A; Zannad F
    Eur J Heart Fail; 2017 Oct; 19(10):1284-1293. PubMed ID: 28580625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed-Methods Study.
    Dev S; Hoffman TK; Kavalieratos D; Heidenreich P; Wu WC; Schwenke DC; Tracy SJ
    J Am Heart Assoc; 2016 Mar; 5(3):e002493. PubMed ID: 27032719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients.
    Parajuli DR; Shakib S; Eng-Frost J; McKinnon RA; Caughey GE; Whitehead D
    BMC Cardiovasc Disord; 2021 Feb; 21(1):104. PubMed ID: 33602125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure.
    Henrysson J; Thunström E; Chen X; Fu M; Basic C
    ESC Heart Fail; 2023 Feb; 10(1):66-79. PubMed ID: 36161782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction.
    Wang TY; Vora AN; Peng SA; Fonarow GC; Das S; de Lemos JA; Peterson ED
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26796254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient selection for mineralocorticoid receptor antagonists in heart failure with mildly reduced or preserved ejection fraction.
    Vardeny O; Houle H
    Pharmacotherapy; 2023 Jun; 43(6):563-569. PubMed ID: 37021777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.
    Savarese G; Carrero JJ; Pitt B; Anker SD; Rosano GMC; Dahlström U; Lund LH
    Eur J Heart Fail; 2018 Sep; 20(9):1326-1334. PubMed ID: 29578280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT).
    Fudim M; Kelly JP; Brophy TJ; DeVore AD; Hammill BG; Peterson ED; Pitt B; Yancy C; Fonarow GC; Hernandez AF
    Am J Cardiol; 2020 Jun; 125(11):1655-1660. PubMed ID: 32273054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study.
    Hirt MN; Muttardi A; Helms TM; van den Bussche H; Eschenhagen T
    Clin Res Cardiol; 2016 May; 105(5):441-50. PubMed ID: 26552905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function.
    Jonsson Holmdahl A; Norberg H; Valham F; Bergdahl E; Lindmark K
    PLoS One; 2021; 16(10):e0258949. PubMed ID: 34710128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
    Brunner-La Rocca HP; Linssen GC; Smeele FJ; van Drimmelen AA; Schaafsma HJ; Westendorp PH; Rademaker PC; van de Kamp HJ; Hoes AW; Brugts JJ;
    JACC Heart Fail; 2019 Jan; 7(1):13-21. PubMed ID: 30606482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study.
    Bruno N; Sinagra G; Paolillo S; Bonomi A; Corrà U; Piepoli M; Veglia F; Salvioni E; Lagioia R; Metra M; Limongelli G; Cattadori G; Scardovi AB; Carubelli V; Scrutino D; Badagliacca R; Guazzi M; Raimondo R; Gentile P; Magrì D; Correale M; Parati G; Re F; Cicoira M; Frigerio M; Bussotti M; Vignati C; Oliva F; Mezzani A; Vergaro G; Di Lenarda A; Passino C; Sciomer S; Pacileo G; Ricci R; Contini M; Apostolo A; Palermo P; Mapelli M; Carriere C; Clemenza F; Binno S; Belardinelli R; Lombardi C; Perrone Filardi P; Emdin M; Agostoni P
    ESC Heart Fail; 2018 Jun; 5(3):267-274. PubMed ID: 29397584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry.
    Chang HY; Wang CC; Wei J; Chang CY; Chuang YC; Huang CL; Chong E; Lin JL; Mar GY; Chan KC; Kuo JY; Wang JH; Chen ZC; Tseng WK; Cherng WJ; Yin WH
    J Chin Med Assoc; 2017 Dec; 80(12):750-757. PubMed ID: 29033112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
    Cooper LB; Lippmann SJ; Greiner MA; Sharma A; Kelly JP; Fonarow GC; Yancy CW; Heidenreich PA; Hernandez AF
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29275368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.